News
-
Aptalis Selects Transperfect’s Trial Interactive Technology As Its Pharmacovigilance System Master File (Psmf) Solution
4/22/2013
TransPerfect, a leading provider of solutions for global development and commercialization of products to the life sciences industry, announced that Aptalis Pharma ("Aptalis") has implemented Trial Interactive as its global pharmacovigilance system master file (PSMF) solution.
-
Bioclinica, Inc. To Demonstrate Technology-Enhanced Capabilities At Upcoming Global Industry Events
4/2/2013
BioClinica, Inc. a global provider of clinical trial management solutions, recently announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June.
-
MMS Set To Expand Disclosure Services With Registry Reporting Software TrialAssure
3/1/2013
MMS Holdings Inc. recently announced that it has successfully executed disclosure management services for several clients and is poised to make strides in this area with its proprietary software, TrialAssure.
-
Quanticate Named Innovation Category Winner In 2013 CRO Leadership Awards
2/11/2013
Quanticate, one of the worlds leading data-focused CROs specializing in the provision of biostatistics, programming, data management, medical writing and pharmacovigilance services has been named category winner for Innovation in the 2013 CRO Leadership Awards presented by Life Science Leader magazine.
-
Reaxys® Medicinal Chemistry Provided As Part Of Elsevier’s Suite Of Life Science
2/5/2013
Comprehensive, referenced and well-structured data allows users to increase the speed and accuracy of decision making in the drug development process.
-
WuXi PharmaTech And PRA Form Joint Venture To Offer Clinical Research Services For Chinese Market
12/18/2012
WuXi PharmaTech, a leading contract research organization with operations in China and the United States, and PRA, a leading global clinical contract research organization, recently announced that they have signed a joint venture agreement to offer a broad platform of Phase I-IV clinical trial services in China, Hong Kong and Macau.
-
Accelovance Strengthens Executive Team With Chief Medical Officer
11/14/2012
Accelovance, an award-winning clinical services company, announced recently the addition of Stephan A. Bart Sr., MD as Chief Medical Officer for the organization.
-
Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
10/12/2012
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate.
-
NIH Launches Trial For Rare Degenerative Muscle Disease Treatment
9/25/2012
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.